Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8656MR)

This product GTTS-WQ8656MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8656MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3832MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ13365MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ3093MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ6962MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ15986MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ4028MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ13501MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ447MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 3G3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW